Compare MTG & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTG | LNTH |
|---|---|---|
| Founded | 1957 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.5B |
| IPO Year | 2008 | 2014 |
| Metric | MTG | LNTH |
|---|---|---|
| Price | $28.23 | $109.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $28.50 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 1.7M | 842.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 8.65 | N/A |
| EPS | 0.76 | ★ 1.80 |
| Revenue | ★ $1,213,636,000.00 | $343,374,000.00 |
| Revenue This Year | $2.50 | N/A |
| Revenue Next Year | $1.77 | $14.19 |
| P/E Ratio | ★ $37.13 | $61.04 |
| Revenue Growth | 0.49 | ★ 3.62 |
| 52 Week Low | $24.69 | $47.27 |
| 52 Week High | $29.97 | $111.86 |
| Indicator | MTG | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 72.75 | 68.13 |
| Support Level | $27.50 | $95.00 |
| Resistance Level | $28.70 | N/A |
| Average True Range (ATR) | 0.53 | 3.08 |
| MACD | 0.26 | 0.05 |
| Stochastic Oscillator | 93.38 | 80.78 |
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.